Research programme: type 2 diabetes therapy - MDRNA
Latest Information Update: 05 Aug 2008
At a glance
- Originator Nastech Pharmaceutical Company
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 09 Nov 2004 Preclinical trials in Type-2 diabetes mellitus in USA (Intranasal)